Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 14, 2022
Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 20, 2020
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment.
Journal: British journal of clinical pharmacology
Published: November 04, 2019
Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply.
Journal: The New England journal of medicine
Published: October 10, 2019
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Journal: The New England journal of medicine
Published: June 04, 2019
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: June 01, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026